A comprehensive view of Organon & Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Organon reaches agreement with Eli Lilly to distribute and promote migraine medicines Emgality and RAYVOW in Europe; the transaction, including a US$50.0M upfront payment, is expected to close in Q1 2024
Published: December 18, 2023 by Associated Press
GlobalData expects Samsung Bioepis and Organon's SB5 to be leading Humira biosimilar for chronic plaque psoriasis, with US$832M in global sales by 2029; SB5 is available in prefilled syringe and prefilled autoinjector, making it easy to self-administer
Published: September 07, 2023 by Express Pharma (India)
Cigna Pharmacy Management adds four biosimilars to HUMIRA as preferred products on its formularies; biosimilars include Boehringer Ingelheim’s Cyltezo, Sandoz’s Adalimumab-adaz and Hyrimoz, Organon’s Hadlima
Published: July 10, 2023 by Cigna Corp.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count